Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 592 clinical trials
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

for anti-PD-L1 blockade. And in this study, we can get "whole" surgical specimen not biopsy sample after Durvalumab treatment so the analysis for immune marker, tumor microenvironment, and various

  • 0 views
  • 23 Jan, 2021
  • 1 location
Study of Atezolizumab Combined With Split-dose Gemcitabine Plus Cisplatin in Urothelial Carcinoma

of adverse events assessed by NCI CTCAE v5.0) and exploratory endpoints ( correlation of prognostic biomarkers/factors with efficacy and relationship between the expression of PD-L1 and microbiome

  • 0 views
  • 01 Mar, 2021
  • 12 locations
Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

(anti-PD-1 or anti-PD-L1 or anti-CTLA4, alone or in combination) in the context of either routine care or a clinical study protocol. Patients with any of the following tumor types may be

  • 10 views
  • 26 Jan, 2021
  • 2 locations
Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

anticancer treatment arsenal. Anti-PD-1 and anti-PD-L1 antibodies have shown promising results in several cancers including Non-small Cell Lung Cancer (NSCLC) patients. Although such ICB extend patient's

  • 0 views
  • 27 Jan, 2021
  • 7 locations
REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors

patients with advanced solid tumors that are nave to anti-PD-1/PD-L1 therapies Dose Expansion: To assess the preliminary efficacy of REGN7075 in combination with cemiplimab within selected

  • 0 views
  • 02 Feb, 2021
  • 2 locations
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

-driven manner. Study population: Stage IV, or unresectable stage III, BRAFV600E/K mutation positive melanoma patients, nave for BRAF/MEK, PD-1/PD-L1 or CTLA-4 targeting therapy, 18 years

  • 5 views
  • 24 Jan, 2021
  • 13 locations
A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.

This is an open-label, multicenter, non-randomized Phase 1b clinical trial for patients with histologically or cytologically confirmed locally advanced or metastatic tumors including non-squamous or squamous NSCLC, RCC, OC, or melanoma.

  • 70 views
  • 25 Jan, 2021
  • 16 locations
Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors

After progression to previous PD-1/L1 inhibitors (pembrolizumab, nivolumab, or atezolizumab), physicians' choice chemotherapy plus pembolizumab (or placebo) will be administered (3 weeks per cycle) until disease progression or unacceptable toxicity.

pembrolizumab
measurable disease
pd-l1
systemic therapy
carcinoma
  • 13 views
  • 23 Jan, 2021
  • 1 location
DS-1062a in Combination With Durvalumab in Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung04)

This study will assess safety, tolerability, and treatment activity of DS-1062a in combination with durvalumab in participants with advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations who have had previously treated with platinum-based therapy with or without prior immunotherapy.

  • 0 views
  • 27 Jan, 2021
  • 7 locations
DS-1062a in Combination With Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung02)

This study will assess safety and treatment activity of DS-1062a in combination with pembrolizumab in participants with advanced or metastatic NSCLC without actionable genomic alterations who have had previously treated with platinum-based therapy with or without prior immunotherapy.

  • 12 views
  • 27 Jan, 2021
  • 8 locations